Bank of America buys 868,457 shares of Cerus Corporation stock

Published on 10/07/2026 at 00:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cerus raised 2026 product revenue guidance to USD 229.00-231.00 million. Cerus Corporation stock had a prior close of EUR 2.07 on October 6, 2026.

CERS, US1570851014, Illustration mit AI erstellt.

Cerus Corporation (ISIN US1570851014) drew a new institutional position after Bank of America acquired 868,457 shares during the second quarter, according to MarketBeat on October 1, 2026. The purchase represented 0.43 percent of Cerus and gave the company a fresh institutional ownership data point as investors assess its blood safety platform.

Institutional stake meets stronger guidance

The stake purchase comes against a backdrop of improving operating momentum. Cerus management raised the low end of its 2026 product revenue guidance to USD 229.00 million to USD 231.00 million, from a previous range of USD 227.00 million to USD 231.00 million, according to the Yahoo Finance transcript dated July 30, 2026. The company also lifted full-year INTERCEPT Fibrinogen Complex revenue guidance to USD 23.00 million to USD 25.00 million, compared with USD 22.00 million to USD 24.00 million previously.

The guidance change is supported by reported sales growth. Product revenue reached USD 57.40 million in the second quarter of 2026, up 10.00 percent from the second quarter of 2025, while first-half product revenue rose 16.00 percent to USD 111.10 million from USD 95.70 million. The same transcript said adjusted EBITDA was USD 3.00 million, marking the ninth consecutive quarter of positive adjusted EBITDA.

Growth still carries execution risk

Cerus develops the INTERCEPT Blood System for pathogen reduction in transfused blood components. Its investor-relations overview says the platform is available globally for platelets and plasma, while the red blood cell system remains in late-stage clinical development. That combination gives the company a commercial base and a longer-term product pipeline, but the second-quarter product gross margin of 51.40 percent was below 55.20 percent a year earlier.

The company also reported a second-quarter GAAP net loss of USD 2.90 million, compared with USD 5.70 million in the second quarter of 2025. Cash used in operations was USD 2.70 million during the second quarter of 2026, making revenue conversion and cost control important counterweights to the double-digit growth targets.

Stock reference remains in euros

The prior close at Lang & Schwarz was EUR 2.07 on October 6, 2026. On the Nasdaq, Cerus had a 52-week range of USD 1.38 to USD 3.47 and a market capitalization of USD 479.60 million as of October 1, 2026, according to MarketBeat. The further course of trading is shown by the continuously updated real-time quote of Cerus stock.